Sugi Predict

Sugi Predict / Compounds / SCHEMBL19836331

SCHEMBL19836331

SCHEMBL19836331

COc1nc2ccc(B3OC(C)(C)C(C)(C)O3)cc2n1C(C)C

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ SNCA P37840 1/20 0.41
▸ IRAK4 Q9NWZ3 1/20 0.39
▸ IDO1 P14902 1/20 0.35
▸ TDO2 P48775 1/20 0.35
▸ LPL P06858 9/20 0.35
▸ LIPG Q9Y5X9 9/20 0.35
▸ CSF1R P07333 1/20 0.33
▸ BACE1 P56817 1/20 0.33
▸ PRMT5 O14744 1/20 0.33
▸ WDR77 Q9BQA1 1/20 0.33
▸ EGFR P00533 1/20 0.32
▸ TP53 P04637 1/20 0.32
▸ MAPT P10636 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ ESR2 Q92731 1/20 0.32
▸ CA1 P00915 1/20 0.32
▸ CA2 P00918 1/20 0.32
▸ CA9 Q16790 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29612564 1.00 SNCA (0.41) SNCAIRAK4IDO1TDO2LPL
SCHEMBL29827536 0.83 IRAK4 (0.44) SNCAIRAK4IDO1TDO2LPL
SCHEMBL19836464 0.83 IRAK4 (0.44) SNCAIRAK4IDO1TDO2LPL
SCHEMBL23062820 0.83 SNCA (0.44) SNCAIRAK4IDO1TDO2LPL
SCHEMBL29612502 0.81 SNCA (0.41) SNCAIRAK4IDO1TDO2LPL
SCHEMBL24668140 0.81 SNCA (0.41) SNCAIRAK4IDO1TDO2LPL
SCHEMBL20987137 0.80 IRAK4 (0.39) SNCAIRAK4IDO1TDO2LPL
SCHEMBL23042579 0.80 SNCA (0.41) SNCAIRAK4IDO1TDO2LPL
SCHEMBL23042340 0.78 SNCA (0.40) SNCAIRAK4IDO1TDO2LPL
SCHEMBL20987201 0.78 LPL (0.31) SNCAIRAK4LPLLIPGEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12528791-B2 Thyroid hormone receptor beta agonist compounds TERNS PHARMACEUTICALS, INC. (US) 2026-01-20 — — US disclosed
US-20240059682-A1 THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS TERNS PHARMACEUTICALS, INC. 2024-02-22 — — US disclosed
EP-3492462-B1 AMINO PYRIMIDINE COMPOUND FOR INHIBITING PROTEIN TYROSINE KINASE ACTIVITY SHENZHEN TARGETRX INC (CN) 2023-08-30 — — EP disclosed
EP-3492462-B1 AMINO PYRIMIDINE COMPOUND FOR INHIBITING PROTEIN TYROSINE KINASE ACTIVITY SHENZHEN TARGETRX INC (CN) 2023-08-30 — — EP disclosed
CN-113382991-B Aminopyrimidines useful for inhibiting protein tyrosine kinase activity 深圳市塔吉瑞生物医药有限公司 2022-12-27 — — CN disclosed
WO-2022187403-A1 THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS TERNS PHARMACEUTICALS, INC. (US) 2022-09-09 — — WO disclosed
US-20220281849-A1 THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS TERNS PHARMACEUTICALS, INC. 2022-09-08 — — US disclosed
EP-4017875-A1 THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS Terns Pharmaceuticals, Inc. (US) 2022-06-29 — — EP disclosed
CN-114430743-A Thyroid hormone receptor beta agonist compounds 拓臻制药公司 2022-05-03 — — CN disclosed
CN-113382991-A Aminopyrimidines useful for inhibiting protein tyrosine kinase activity 深圳市塔吉瑞生物医药有限公司 2021-09-10 — — CN disclosed
US-11111233-B2 Amino pyrimidine compound for inhibiting protein tyrosine kinase activity SHENZHEN TARGETRX, INC. (CN) 2021-09-07 — — US disclosed
CN-110818690-B Aminopyrimidines useful for inhibiting protein tyrosine kinase activity 深圳市塔吉瑞生物医药有限公司 2021-08-10 — — CN disclosed
WO-2021041237-A1 THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS Terns, Inc. (US) 2021-03-04 — — WO disclosed
WO-2021041237-A1 THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS Terns, Inc. (US) 2021-03-04 — — WO disclosed
CN-110818690-A Aminopyrimidines useful for inhibiting protein tyrosine kinase activity 深圳市塔吉瑞生物医药有限公司 2020-02-21 — — CN disclosed
CN-108602802-B Aminopyrimidines useful for inhibiting protein tyrosine kinase activity 深圳市塔吉瑞生物医药有限公司 2020-01-21 — — CN disclosed
EP-3492462-A1 AMINO PYRIMIDINE COMPOUND FOR INHIBITING PROTEIN TYROSINE KINASE ACTIVITY Shenzhen Targetrx, Inc. (CN) 2019-06-05 — — EP disclosed
US-20190152954-A1 AMINO PYRIMIDINE COMPOUND FOR INHIBITING PROTEIN TYROSINE KINASE ACTIVITY SHENZHEN TARGETRX, INC. (CN) 2019-05-23 — — US disclosed
US-20190152954-A1 AMINO PYRIMIDINE COMPOUND FOR INHIBITING PROTEIN TYROSINE KINASE ACTIVITY SHENZHEN TARGETRX, INC. (CN) 2019-05-23 — — US disclosed
WO-2018019204-A1 AMINO PYRIMIDINE COMPOUND FOR INHIBITING PROTEIN TYROSINE KINASE ACTIVITY 深圳市塔吉瑞生物医药有限公司 2018-02-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12528791-B2 Thyroid hormone receptor beta agonist compounds THRB, THRA, TSHR SNCA 2690/4885IRAK4 3533/4885IDO1 1866/4885
US-20220281849-A1 THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS THRB, THRA, TSHR SNCA 3065/4885IRAK4 1862/4885IDO1 2264/4885
US-20190152954-A1 AMINO PYRIMIDINE COMPOUND FOR INHIBITING PROTEIN TYROSINE KINASE ACTIVITY LCK, WEE1, JAK1 SNCA 4492/4885IRAK4 1234/4885IDO1 451/4885
US-20240059682-A1 THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS THRB, THRA, TSHR SNCA 3199/4885IRAK4 1782/4885IDO1 2485/4885
US-11111233-B2 Amino pyrimidine compound for inhibiting protein tyrosine kinase activity LCK, WEE1, JAK1 SNCA 4492/4885IRAK4 1234/4885IDO1 451/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.